Pfizer has filed a lawsuit against Novo Nordisk and Metsera in an attempt to force through its takeover of the weight-loss drug developer and prevent Novo Nordisk from taking its rival bid forward.

All this means that Viking is a great biotech buy -- its candidate is promising, you can benefit from getting in on the dip, and momentum has been picking up. But you don't have to rush to scoop up ...

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

The U.S. FDA plans enforcement actions against four firms selling unapproved fluoride drugs for children. Research identifies ...

Coming up: earnings from AMD, Palantir, top pharmaceutical and tech firms; private-sector employment report; consumer sentiment.

Novo Nordisk attempts to acquire weight-loss drug company Metsera during government shutdown, potentially avoiding FTC ...

There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company ...

All of this has weighed on stock performance, leaving the shares down almost 50% over the past three years. Considering this, ...

CNBC's Charlotte Reed will travel to Copenhagen to speak with Novo Nordisk's new CEO after a bumpy few months.

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...